Literature DB >> 27918600

TREATMENT OF TYPE 2 DIABETES WITH BIPHASIC INSULIN ANALOGUES.

Ali A Rizvi1.   

Abstract

The majority of patients with Type 2 diabetes require insulin therapy for treating hyperglycaemia. There are several regimens available for insulin initiation and maintenance. Insulin analogues have been developed to mimic normal physiology as closely as possible. Biphasic analogues can target both fasting and postprandial hyperglycaemia, with the added advantage of being premixed and thus convenient for the patient. A practical and feasible option is to initiate insulin with one or more biphasic preparations at mealtimes, thus providing both basal and prandial coverage. Individual titration of dose and frequency of daily injections with biphasic insulin preparations has the potential for improving glycaemic control with a high degree of patient acceptance. Drawbacks include a more rigid regimen, a relative lack of flexibility, and a somewhat higher degree of glycaemic variability and hypoglycaemia when compared to multiple daily basal-bolus injections. Awareness of the advantages and limitations of biphasic insulin analogues can assist clinicians in their appropriate use for the treatment of patients with Type 2 diabetes.

Entities:  

Keywords:  Type 2 diabetes (T2D); biphasic insulin; hyperglycaemia; insulin analogues; premixed insulin

Year:  2016        PMID: 27918600      PMCID: PMC5134918     

Source DB:  PubMed          Journal:  Eur Med J Diabetes        ISSN: 2054-6181


  49 in total

1.  Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients.

Authors:  V A Koivisto; J A Tuominen; P Ebeling
Journal:  Diabetes Care       Date:  1999-03       Impact factor: 19.112

2.  Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2015-01       Impact factor: 19.112

3.  Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.

Authors:  Philip Raskin; Elsie Allen; Priscilla Hollander; Andrew Lewin; Robert A Gabbay; Peter Hu; Bruce Bode; Alan Garber
Journal:  Diabetes Care       Date:  2005-02       Impact factor: 19.112

4.  Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.

Authors:  C Ionescu Tîrgovişte; Rodica Străchinariu; Eugenia Farcaşiu; Z Milicevic; Gabriela Teodorescu
Journal:  Rom J Intern Med       Date:  2003

5.  Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.

Authors:  Kjeld Hermansen; Michele Colombo; Heidi Storgaard; Anette ØStergaard; Klaus Kølendorf; Sten Madsbad
Journal:  Diabetes Care       Date:  2002-05       Impact factor: 19.112

6.  Low risk of severe hypoglycaemia in patients with type 2 diabetes mellitus starting insulin therapy with premixed insulin analogues BID in outpatient settings.

Authors:  V Pīrāgs; H El Damassy; M Dąbrowski; M S Gönen; E Račická; E Martinka; J Giaconia; A Stefanski
Journal:  Int J Clin Pract       Date:  2012-11       Impact factor: 2.503

Review 7.  Effects of rapid-acting insulin analogs on overall glycemic control in type 1 and type 2 diabetes mellitus.

Authors:  Smiljana Ristic; Peter C Bates
Journal:  Diabetes Technol Ther       Date:  2003       Impact factor: 6.118

8.  Three-year efficacy of complex insulin regimens in type 2 diabetes.

Authors:  Rury R Holman; Andrew J Farmer; Melanie J Davies; Jonathan C Levy; Julie L Darbyshire; Joanne F Keenan; Sanjoy K Paul
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

9.  Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial.

Authors:  A Liebl; R Prager; K Binz; M Kaiser; R Bergenstal; B Gallwitz
Journal:  Diabetes Obes Metab       Date:  2008-07-17       Impact factor: 6.577

10.  A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus.

Authors:  Mary Korytkowski; David Bell; Carol Jacobsen; Rudee Suwannasari
Journal:  Clin Ther       Date:  2003-11       Impact factor: 3.393

View more
  5 in total

1.  Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen.

Authors:  Jochen Seufert; Anja Borck; Peter Bramlage
Journal:  BMJ Open Diabetes Res Care       Date:  2019-10-01

2.  A single-dose euglycaemic clamp study in two cohorts to compare the exposure of SAR341402 (insulin aspart) Mix 70/30 with US- and European-approved versions of insulin aspart Mix 70/30 and SAR341402 rapid-acting solution in subjects with type 1 diabetes.

Authors:  Christoph Kapitza; Leszek Nosek; Wolfgang Schmider; Lenore Teichert; Bhaswati Mukherjee; Irene Nowotny
Journal:  Diabetes Obes Metab       Date:  2020-12-10       Impact factor: 6.577

3.  The Effect of DPP4 Inhibitor on Glycemic Variability in Patients with Type 2 Diabetes treated with twice-daily Premixed Human Insulin.

Authors:  Florence Hui Sieng Tan; Chin Voon Tong; Xun Ting Tiong; Bik Kui Lau; Yueh Chien Kuan; Huai Heng Loh; Saravanan A/L Vengadesa Pillai
Journal:  J ASEAN Fed Endocr Soc       Date:  2021-09-03

4.  Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M).

Authors:  S R Aravind; Kiran P Singh; Grace Aquitania; Liliia Mogylnytska; Alsu G Zalevskaya; Beata Matyjaszek-Matuszek; Karin Wernicke-Panten; My-Liên Nguyên-Pascal; Suzanne Pierre; Baerbel Rotthaeuser; Daniel Kramer; Bhaswati Mukherjee
Journal:  Diabetes Ther       Date:  2022-04-14       Impact factor: 3.595

Review 5.  Forum for Injection Technique and Therapy Expert Recommendations, India: The Indian Recommendations for Best Practice in Insulin Injection Technique, 2017.

Authors:  Nikhil Tandon; Sanjay Kalra; Yatan Pal Singh Balhara; Manash P Baruah; Manoj Chadha; Hemraj B Chandalia; K M Prasanna Kumar; S V Madhu; Ambrish Mithal; Rakesh Sahay; Rishi Shukla; Annamalai Sundaram; Ambika G Unnikrishnan; Banshi Saboo; Vandita Gupta; Subhankar Chowdhury; Jothydev Kesavadev; Subhash K Wangnoo
Journal:  Indian J Endocrinol Metab       Date:  2017 Jul-Aug
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.